BC
COGT icon

Bridgefront Capital’s Cogent Biosciences COGT Stock Holding History

Bridgefront Capital’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,186
Closed -$504K – 560
2025
Q4 		$504K Buy
+14,186
New +$399K 0.13% 271

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Bridgefront Capital's COGT Position: Q1 2026 in Review

Bridgefront Capital sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 14,186 shares — an estimated $504K sold.

Bridgefront Capital first reported a position in COGT in Q4 2025 and held it in 1 quarter. The position peaked at $504K in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Bridgefront Capital reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
  • Bridgefront Capital sold 14,186 Cogent Biosciences shares in Q1 2026, an estimated $504K.
  • Bridgefront Capital first reported a position in Cogent Biosciences in Q4 2025 and held it in 1 quarter.
  • Bridgefront Capital's Cogent Biosciences position peaked at $504K in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.